Retatrutide 10mg

Retatrutide is a novel triple receptor agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This tri-agonist mechanism distinguishes it from earlier generation compounds like semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual). In preclinical and early clinical research settings, multi-receptor engagement produces distinct effects on energy homeostasis, metabolic regulation, and body weight pathways. Supplied as a lyophilised powder at 99.738% HPLC purity.

Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro) is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination, creating a triple mechanism. In research models, glucagon receptor activation contributes to hepatic glucose output modulation and thermogenesis effects that single or dual agonists do not produce. This makes Retatrutide a distinct and more complex research compound, not a substitute for either compound — each has unique receptor profiles and research applications.

Reconstitution: Draw 1–2mL of bacteriostatic water into a clean 31G insulin syringe. Inject slowly down the inside wall of the Retatrutide vial — do not aim directly at the lyophilised cake. Gently swirl the vial until fully dissolved; do not shake or vortex. The solution should be clear and colourless. Label with compound, concentration, and date. Storage: Lyophilised powder — store at −20°C for up to 12–24 months, protected from light and moisture. Reconstituted solution — store at 2–8°C and use within 4 weeks. Avoid freeze-thaw cycling of the reconstituted solution.

Legal status: Retatrutide is legal to purchase in Australia for legitimate laboratory research purposes. It is not currently listed as a scheduled substance under the Therapeutic Goods Act or the Poisons Standard when sold for research use only. Purchasers must be 18+ and confirm research-only use. It is not approved for human consumption or therapeutic use by the TGA. Quality: Our Retatrutide 10mg (Batch PW-260301) is independently verified at 99.4% HPLC purity by an accredited third-party laboratory. The COA includes: HPLC purity %, mass spectrometry identity confirmation, and sterility screening results. Full COA is available in our COA Library.

Peptide Warehouse dispatches Retatrutide nationwide via Australia Post with full tracking. Orders placed before 9PM AEST are dispatched the next business day. Standard Post (2–6 business days) costs $9.99; Express Post (1–3 business days) costs $15.99. Free shipping applies on orders over $199 AUD. Retatrutide is currently on pre-order with dispatch within 7–10 business days from our Australian warehouse. All orders are shipped in discreet, plain packaging with no external branding.

Retatrutide (LY3437943) is a 39-amino acid acylated peptide with a molecular weight of approximately 4813.5 Da. Its sequence incorporates modifications at multiple positions to optimise receptor binding affinity across all three targets — GLP-1R, GIPR, and glucagon receptor — as well as a fatty acid side chain that extends plasma half-life. The exact sequence is protected intellectual property of Eli Lilly, but the compound has been fully characterised in peer-reviewed literature. Identity is confirmed in our batch via mass spectrometry (see COA). Not for human consumption — for research use only.

Bacteriostatic water (BAC water) is strongly recommended over plain sterile water for injection. BAC water contains 0.9% benzyl alcohol, which acts as a preservative and allows the reconstituted solution to be accessed multiple times over a 4-week period while maintaining sterility. Sterile water for injection contains no preservative — once punctured, it must be used immediately or discarded. For any research protocol involving repeated sampling from a single vial of Retatrutide, BAC water is the correct choice. Our BAC Water 10mL is available at /products/bac-water-10ml. Not for human consumption — for research use only.

Standard laboratory instruments used in Retatrutide research include: analytical HPLC systems (for purity verification), mass spectrometers (ESI-MS or MALDI-TOF for identity confirmation), micropipettes and calibrated syringes for precise dilution, fluorescence plate readers or ELISA systems for receptor binding and cAMP assay readouts, cell culture incubators for in-vitro receptor expression models, and −20°C or −80°C freezers for long-term storage. For reconstitution specifically, 31G insulin needles (available at /products/insulin-needles-31g) and BAC water are the minimum required consumables. Not for human consumption — for research use only.

Retatrutide's glucagon receptor (GCGR) agonism is a key differentiator from dual GLP-1/GIP compounds. The glucagon receptor is a class B GPCR that, when activated, stimulates hepatic glucose output via adenylyl cyclase/cAMP/PKA signalling, promotes fatty acid oxidation in liver tissue, and increases energy expenditure through thermogenic mechanisms. In the context of a triple agonist, GCGR activation is modulated by the simultaneous GLP-1R engagement — GLP-1R agonism suppresses the hyperglycaemic effect of glucagon, allowing the thermogenic and lipolytic aspects of glucagon signalling to be studied without the corresponding rise in blood glucose seen with isolated glucagon. This interaction is a central focus of current metabolic research on the compound. Not for human consumption — for research use only.

Yes. LY3437943 is the internal Eli Lilly development code for Retatrutide. Both names refer to the identical compound — a GLP-1/GIP/glucagon triple receptor agonist developed by Eli Lilly and studied in multiple clinical trials including the TRIUMPH programme. In research literature and databases (PubChem, ClinicalTrials.gov), you may find it listed under either name. Our Retatrutide 10mg is the research-grade peptide equivalent of LY3437943, verified at 99.4% HPLC purity with mass spectrometry identity confirmation. Not for human consumption — for research use only.

Our current Retatrutide 10mg batch is PW-260301. The Certificate of Analysis for this batch is publicly available in our COA Library (accessible via the COA link on this product page and in our website navigation). The COA documents: HPLC purity (99.4%), mass spectrometry identity confirmation, sterility screening results, and batch-specific manufacturing details. If you require a copy emailed directly, contact us at info@auspeptidewarehouse.com.au with your order number or the batch reference. Not for human consumption — for research use only.

Retatrutide does not currently have a widely published CAS registry number, as it is a proprietary investigational peptide (development code LY3437943) whose full sequence and structure are defined by Eli Lilly's patent estate. Identity confirmation in our batch is performed by mass spectrometry and HPLC retention time matching against reference standards, as documented in our COA (Batch PW-260301). Researchers requiring compound identity documentation for institutional records should reference the COA mass spectrometry data. Not for human consumption — for research use only.